Market capitalization | $96.36m |
Enterprise Value | $2.85m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.12 |
EV/Sales (TTM) EV/Sales | 0.10 |
P/S ratio (TTM) P/S ratio | 3.40 |
P/B ratio (TTM) P/B ratio | 3.70 |
Revenue (TTM) Revenue | $28.33m |
EBIT (operating result TTM) EBIT | $-46.44m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Assembly Biosciences, Inc. forecast:
3 Analysts have issued a Assembly Biosciences, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 28 28 |
-
|
|
Gross Profit | 28 28 |
5,845%
5,845%
|
|
EBITDA | -46 -46 |
39%
39%
|
EBIT (Operating Income) EBIT | -46 -46 |
39%
39%
|
Net Profit | -41 -41 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Jason Okazaki |
Employees | 65 |
Founded | 2005 |
Website | www.assemblybio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.